The United States is the world’s leading pain-management market. Roughly 50 million Americans live with chronic pain, which is more than the combined amount of people with diabetes, heart disease, and cancer. A serious, undertreated public-health problem, uncontrolled pain costs an estimated $100 billion in the United States every year when considering healthcare expenses, lost income, and lost productivity.
An estimated 76.5 million Americans 20 years of age and older have had a problem with pain of any type that persisted for more than 24 hours (excluding acute pain).
This special report focuses on the market leaders for pain management as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of pain management prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of pain management medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the pain management field.